About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Piramal Pharma’s future is anchored in scaling its CDMO business to $1.2 billion, expanding complex hospital generics, and ...

GIP (red),  glucagon (violet) and PYY (green). Each hormone targets its own receptor. The effect of each receptor on the body are indicated using the same color code. The tetra-agonist compound ...

"Let's say you wake up really hungry," says Lembas CTO Dr. Zohar Barbash. "You take the peptide and feel like you have just ...

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically ...